Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

This study found no relationship between symptom experience and medication non-compliance in liver transplant patients, though symptom distress was notably more severe in women.

This study found that topical application of cyclosporin A and FK506 induces new hair growth in mice, while ascomycin and rapamycin do not, suggesting hair induction is not due to immunosuppression.

This study found that kidney transplant recipients who experienced higher levels of symptom distress from immunosuppressive medications were more likely to be nonadherent to their medication regimen.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

This study observed that nearly all kidney transplant patients experienced complications from immunosuppressive therapy, with excessive hair growth and increased blood sugar being the most common issues.

This study suggests that human DSCCs may aid in hair follicle regeneration and reduce microinflammation, with potential applications in regenerative medicine evaluated through a new morphometric analysis.

IL-27 may help prevent hair loss in alopecia areata by promoting immunosuppressive T cells.

This study found that while kidney transplant recipients generally reported good quality of life on immunosuppressive therapies, women experienced more distressing symptoms and lower satisfaction compared to men.

Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

This study found that antroquinonol inhibited CD8+ T cell proliferation and reduced proinflammatory cytokine secretion in vitro, while also ameliorating H2O2-induced depigmentation and resisting reductions in hair follicle length, skin thickness, and tyrosinase expression in mice.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

This research paper reviews the mechanisms and management of non-biologic immunosuppressive drugs used in dermatology, highlighting their safety profiles and handling during pregnancy, breastfeeding, and vaccination, but does not report specific results on these aspects.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

This review discusses the relationship between aging, chronic inflammation, and immunosuppression, suggesting that these interconnected processes may contribute to tumorigenesis and premature aging, but reports no new experimental results.

This review examines the implications of COVID-19 vaccination for dermatological patients with psoriasis on immunosuppressive treatment and reports no new clinical results.

The researchers reported that DHT may reduce the inflammatory responses induced by C. acnes in androgen-sensitive human sebocyte cells, suggesting a potential link between androgens and infection in sebaceous disorders.

This paper argues that for lupus management, selective immunotherapies like anifrolumab and belimumab, which specifically target parts of the immune system, offer more effective treatment options compared to older, broad immunosuppressive strategies.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This article reviews current diagnostic and treatment approaches for discoid lupus erythematosus, emphasizing the importance of early treatment and photoprotection, but reports no new clinical findings.

This study observed that systemic lupus erythematosus may not be as uncommon among African Blacks as previously reported, highlighting the need for early aggressive treatment.

This article discusses the classification and significance of cutaneous manifestations in systemic lupus erythematosus, emphasizing the importance of recognizing these skin features for disease management, but reports no new clinical results.

This review discusses approaches to diagnosing and managing cutaneous manifestations of lupus erythematosus and reports no new clinical results.

This article provides a detailed analysis of immunosuppressive medications in transplant patients and discusses the increased risk of skin cancer, but it reports no new experimental results.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

This review highlights that although advancements in alopecia areata treatments, such as Janus kinase inhibitors and combination therapies, show promise, further research is necessary to validate their long-term safety and efficacy.

This review discusses the complex etiology and pathogenesis of vitiligo, noting challenges in treatment effectiveness and relapse, and reports no new clinical results.

This article reviews the pathogenesis, complications, and management of lichen planus, especially its persistent oral form, and highlights the need for further prospective studies.